ERBB2 and breast carcinoma: This recent Phase I clinical trial by Jhaveri et al. 38 not only provides a strong foundation with clinical relevancy for our current study focusing on the anti-cancer effects and mechanisms of ganetespib specifically in the ErbB2+ breast cancer subtype, but also fundamentally supports the concept that novel treatment strategies combining ganetespib with ErbB2-targeting therapeutics may improve clinical responses in ErbB2+ breast cancer patients.